Placental growth factor (PlGF) is a member of the vascular endothelial growth factor (VEGF) family, and its expression supports angiogenesis. The expression level of PlGF has a correlation with the severity of cancer, so PlGF is a research index involved in tumor research. Creative BioMart Biomarker has always been committed to providing cancer biomarker testing services. Our technical team has rich experience and can provide customers with high-quality PlGF detection services to help customers advance tumor researches.
PlGF and Cancers
PlGF is a glycosylated homodimer, each monomer is formed by two α chains and 7 β chains connected by interchain disulfide bonds. PlGF has four subtypes, namely PlGF-1, PlGF-2, PlGF-3 and PlGF-4. Among them, PlGF-1 and PlGF-3 are non-heparin-binding isoforms, while PlGF-2 and PlGF-4 have heparin-binding domains. PlGF has high expression during pregnancy and can be used for the study of pre-eclampsia and other pregnancy-related diseases. As a member of the VEGF family, PlGF also plays an important role in angiogenesis. PlGF can enhance the activity of VEGF through competitive binding with VEGFR-1, so that VEGF can bind to VEGFR-2, which has stronger activity, and ultimately promote angiogenesis. PlGF is essential for the development of physiological blood vessels, but it is not necessary for the development of blood vessels in healthy adults. PlGF is associated with pathological angiogenesis and can stimulate angiogenesis. In addition, plgf gene knockout may lead to pathological conditions of tumor growth. Therefore, PlGF research is mostly related to pathological angiogenesis. For example, when a tumor occurs, the expression of PlGF may be up-regulated, and this may be caused by tumor necrosis factor, growth factor, and carcinogen. In addition, PlGF is also related to the polarization state of tumor-associated macrophages (TAM). TAM is expressed as a classic M1 type in non-progressive or degenerative tumors, while TAM activates M2 type in malignant tumors, resulting in more angiogenesis and the growth and spread of tumor cells. PlGF plays an important role in maintaining this phenotype. Due to the pro-angiogenic effect of PlGF in tumors and the function of promoting M2 type, some tumor researches are carried out with PlGF as the target, and PlGF is also used as an effective biomarker for the study of various tumors.
Figure 1. Schematic illustration of VEGF-dependent dual functions of PlGF in modulation of angiogenesis, tumor growth, and vascular remodeling (Yang, et al. 2013)
Application of PlGF Detection
Plasma and serum PlGF levels can be used as a biomarker for tumor research and related drug studies.
Our Advantages
- Guarantee high accuracy and sensitivity for PlGF detection
- Ensure high repeatability of PlGF detection
- Short turn-around time of detection service
- Competitive price in the market of PlGF detection services
- Provide multiple PlGF detection methods, including ELISA, ECL, etc.
- Accept a wide range of sample types (plasma, serum and cell culture supernates)
Workflow of Biomarker Detection at Creative BioMart Biomarker
Creative BioMart Biomarker strictly controls each specific experimental step in the detection procedure to ensure accurately quantify the level of PlGF subtypes in each sample.
At Creative BioMart Biomarker, we offer PlGF detection service that includes different subtypes and refer to different methods, you can communicate with our experts according to your research needs, and we will determine the final detection technological scheme based on the communication results. Please feel free to contact us, Creative BioMart Biomarker is here to offer you professional and thoughtful service.
References:
- Yang, X.; et al. Vascular endothelial growth factor-dependent spatiotemporal dual roles of placental growth factor in modulation of angiogenesis and tumor growth. Proceedings of the National Academy of Sciences. 2013, 110(34): 13932-13937.
- Falco, S. D. The discovery of placenta growth factor and its biological activity. Experimental and Molecular Medicine. 2012, 44(1): 1–9.
